Navigation Links
Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
Date:5/15/2008

The REACH Registry reveals that 70% of deaths in the stable stroke

population were due to a cardiovascular event other than stroke

NICE, France, May 15 /PRNewswire/ -- New two-year data from the REACH Registry presented at the European Stroke Congress, highlight that among those who die after a stroke the vast majority (73%) will die from nonstroke cardiovascular (CV) events. The overall death rate is 4.45%, with 3.23% of these CV deaths from a nonstroke event.

The two-year data from the REACH Registry demonstrate that the risk of secondary ischemic events (including CV death) is very high in patients with previous stroke and/or TIA.

The REACH Registry has demonstrated that there is a high prevalence of atherothrombosis in more than one vascular bed: one-quarter of patients with coronary artery disease (CAD), two-fifths of patients with cerebrovascular disease (CVD) and three-fifths of patients with peripheral artery disease (PAD) also have atherothrombosis in other arterial locations. REACH Registry data also highlight the undertreatment of patients with CVD in the real-world setting. Improving ischemic risk management in these patients is required to prevent hospitalization and death.

Approximately 28% of patients in the REACH Registry have diagnosed CVD at baseline. About 40% of patients with CVD have polyvascular disease. Of the total CVD population at baseline: 71% suffered a prior stroke; 51% had a prior TIA; and, 20% had both.

Two-year data in the CVD population show high event rates for non-fatal stroke (5.9%). The risk of stroke, MI and CV death at two years was 11.5% for the total CVD population. Patients with a history of CVD are at considerable risk of major adverse cardiac events (MACE) and hospitalizations (>20% at two years).

"CVD patients are at high risk of recurrent stroke and other atherothrombotic events. Moreover the REACH Registry has shown that most of these stable stroke patients are at risk of dying from a non-stroke CV event. Prevalence of risk factors, co-morbidities, utilization of secondary prevention therapies and adherence to guidelines all influence the recurrent event rate. The two-year data show that the risk for further atherothrombotic events remains high in this stable population. TIAs often trivialized as 'mini-strokes' with a good prognosis that could be treated on an outpatient basis have nearly as high risk for future atherothrombotic events as stroke patients. Undertreatment is common worldwide and adherence to guidelines needs to be enforced to prevent deaths from heart disease and stroke," said Dr. Joachim Rother, Professor of Neurology at the Department of Neurology, Minden Hospital at the University of Hannover Medical School in Minden, Germany.

CVD is heterogeneous with large carotid and intracranial arterial disease accounting for about 20-30% of all ischemic strokes. Other causes include cardioembolism (25%), microangiopathy (20%), and cryptogenic stroke.(1,2) High blood pressure is a risk factor strongly associated with stroke. CVD is a global health problem and the incidence of stroke is increasing worldwide.

This underscores the very high risk factor profile and high percentage of CVD patients with additional atherothrombotic disease manifestations in the REACH Registry which was first published last month in Cerebrovascular Diseases.(3)

"The REACH Registry continues to demonstrate the real-world burden of atherothrombotic disease worldwide. In the case of CVD, further analysis has re-emphasized the need for doctors to adhere to evidence-based guidelines for treatment such as long-term antiplatelet therapy or antihypertensive treatment," said Dr. Gabriel Steg, Professor of Cardiology at Hopital Bichat-Claude Bernard, Paris, on behalf of the REACH Registry's Scientific Council.

In addition to this analysis, REACH investigators presented a poster during the European Stroke Conference 2008 on the risk of coronary events in patients with stroke or TIA. (Risk of coronary events in patients with stroke or TIA: Two-year follow-up data from the REduction of Atherothrombosis for Continued Health (REACH) Registry: Touze E, Rother J, Alberts MJ, Goto S, Hill MD, Aichner F, Steg PG, Bhatt DL, Mas JL, on behalf of the REACH Registry Investigators). Whereas the incidence rates of MI and nonstroke vascular death are only about 1% per year, the risk rises in patients with additional CAD to 2 to 2.5% again underlining the increased risk of polyvascular disease.

Objectives and scope of REACH

The overall aim of the REACH Registry is to improve the assessment and management of stroke, heart attack and associated risk factors for atherothrombosis. It is the largest and most geographically extensive global registry of patients at risk of atherothrombosis, having recruited over 68,000 patients in 44 countries, covering six regions -- Latin America, Asia, the Middle East, Australia, Europe and North America -- and involving over 5,000 physician investigators.(4,5)

The REACH Registry includes a broad spectrum of patients with atherothrombosis -- documenting the health status and treatment of people at risk of atherothrombosis; monitoring how they are affected; and measuring the burden of the disease. Patients included in the REACH Registry either have several of the risk factors that can lead to atherothrombosis, such as, high cholesterol, high blood pressure, smoking, and diabetes, or have a previous history of heart attack, stroke or PAD. Participation in the REACH Registry is strictly voluntary.

In addition, the REACH Registry is based in a real-life setting and seeks to increase overall understanding of atherothrombotic disease across several medical specialties (cardiology, neurology, internal medicine, vascular medicine and office-based primary care physicians), which allows for a more thorough assessment of the real-world burden of the disease.

The underlying cause of heart attack, stroke and PAD

Atherothrombosis occurs when a blood clot (thrombus) forms on a ruptured plaque (atheroma) in the wall of a blood vessel. Plaques consist of fatty acids and cholesterol, calcium and other materials.

The rupture of plaques and the subsequent development of a clot can cause partial or complete blockage of an artery in various parts of the body. When a vessel in the heart is partially or completely blocked by a clot the result can be a heart attack. In the brain, the same process can cause a stroke or a TIA which may only last a few minutes. Elsewhere in the body, this process can lead to reduction or blockage of blood flow in the arteries of the legs -- PAD -- a significant risk factor for heart attack or stroke.

Atherothrombosis is thus the common thread linking heart attack, stroke and PAD.

Notes to Editors:

REACH Registry

The REACH Registry is the first outpatient registry to characterize real-world event rates and treatment patterns in a broad spectrum of patients with atherothrombosis worldwide. The Registry follows more than 60,000 patients over four years, involving 44 countries and 5,000 physician investigators. The REACH Registry aims to improve the assessment and management of patients with a history of CAD, CVD (stroke/TIA), PAD, and those with a high combination of risk factors.

The REACH Registry is sponsored by sanofi-aventis, Bristol-Myers Squibb, and the Waksman Foundation (Tokyo, Japan), who assisted with the design and conduct of the study and data collection.
The REACH Registry is endorsed by the World Heart Federation.

REACH Registry Scientific Committee:

-- Philippe Gabriel Steg, Hopital Bichat-Claude Bernard, Paris, France

-- Deepak L. Bhatt, Cleveland Clinic Foundation, Cleveland, USA

-- E. Magnus Ohman, Duke University, Durham, NC, USA

-- Joachim Rother, Klinikum Minden, Hannover Medical School, Germany

-- Peter WF Wilson, Emory University School of Medicine, Atlanta, GA, USA

For further information on the REACH Registry please visit http://www.REACHRegistry.org

References

(1.) Grau AJ, Weimar C, Buggle F et al. Risk factors, outcome, and

treatment in subtypes of ischemic stroke: the German stroke data

bank. Stroke 2001;32:2559-2566.

(2.) Adams HP Jr, Bendixen BH, Kappelle LJ et al. Classification of

subtype of acute ischemic stroke: definitions for use in a

multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke

Treatment. Stroke 1993;24:35-41.

(3.) Rother J, Alberts MJ, Touze et al. Risk factor Profile and Management

of Cerebrovascular Patients in the REACH Registry Cerebrovasc Dis

2008;25:366-374.

(4.) DL. Bhatt, PG. Steg, EM. Ohman, AT. Hirsch, Y. Ikeda, J-L. Mas, S.

Goto, C-S. Liau, A-J. Richard, J. Rother, PWF. Wilson, on behalf of

the REACH Registry Investigators. International prevalence,

recognition, and treatment of cardiovascular risk factors in

outpatients with atherothrombosis. JAMA 2006;295:180-189.

(5.) PG. Steg, DL. Bhatt, PWF. Wilson, R. D'Agostino, EM. Ohman, J.

Rother, C-S. Liau, AT. Hirsch, J-L. Mas, Y. Ikeda, MJ. Pencina, S.

Goto, on behalf of the REACH Registry Investigators. One-year

cardiovascular event rates in outpatients with atherothrombosis. JAMA

2007;297: 1197-1206.


'/>"/>
SOURCE REACH Registry
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
2. Biomatricas RNAstable(TM) Stabilizes RNA at Room Temperature
3. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
4. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
10. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... DALLAS , Oct. 10, 2017 International research firm ... IoT Strategy, will speak at the TMA 2017 Annual Meeting , ... key trends in the residential home security market and how smart safety ... ... "The ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... recipients of 13 prestigious awards honoring scientists who have made ... in a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting ... a professor in Harvard University’s Departments of Physics and Astronomy, has been selected for ... of the winning team for the 2015 Breakthrough Prize in Fundamental physics for the ...
(Date:10/7/2017)... ... October 06, 2017 , ... With ... microscopy and surface analysis, Nanoscience Instruments is now expanding into Analytical Services. ... range of contract analysis services for advanced applications. Services will leverage techniques ...
Breaking Biology Technology:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):